Does targeted therapy treat chronic lymphocytic leukaemia?

Chronic lymphocytic leukaemia, also called CLL, affects a type of white blood cell called a B lymphocyte. Targeted medicines act on specific proteins or signals that CLL cells rely on. This can slow their growth, encourage their removal, or reduce their ability to receive survival signals. Treatment may be taken as tablets, given by infusion, or used in combination with another medicine. Some people are monitored before treatment is needed, while others need therapy because of symptoms, changing blood results, enlarged lymph nodes, or effects on normal blood-cell production.

A haematology team reviews the pattern of your CLL, blood counts, genetic or molecular findings, medicines you already take, and any other health conditions. Tell the team about heart problems, bleeding history, infections, and supplements before starting treatment. Ask how the medicine is taken, whether doses need to increase gradually, which monitoring appointments are needed, and what to do after a missed dose. Do not stop a CLL medicine without medical advice; a planned change can be safer than an abrupt interruption.

Contact your treatment team promptly for a fever, chills, new cough, breathlessness, unusual bleeding, black stools, severe diarrhoea, or a rapidly worsening rash. Seek urgent help for trouble breathing, swelling of the face or throat, confusion, fainting, or bleeding that does not settle. These symptoms can have several causes, but treatment may affect infection risk, bleeding, or the immune system and should be assessed quickly.

Which feature of my CLL makes this treatment suitable? How will we check whether it is working? What symptoms should trigger a same-day call? Could my other medicines interact with it? If treatment is paused or changed, what is the plan?